Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sleep hormone melatonin tested as lifeline for Growth-Restricted babies

NCT ID NCT07549295

First seen Apr 29, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study tests whether melatonin, a natural hormone, can improve outcomes for babies diagnosed with severe fetal growth restriction (FGR) due to placental problems. Pregnant women between 24 and 31 weeks will take melatonin or a placebo nightly. The goal is to see if melatonin reduces the risk of serious complications or death for the baby after birth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FETAL GROWTH RESTRICTION (FGR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200092, China

Conditions

Explore the condition pages connected to this study.